Omrix gets EU approval for Evicel sealant
USA-based Omrix, a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, has received approval from the European Medicines Agency (EMEA) for its Evicel liquid fibrin sealant.
The product is now cleared as a supportive treatment in surgery where standard surgical techniques are insufficient for the improvement of hemostasis or as suture support for hemostasis in vascular surgery.
Evicel is a fully-human, plasma-derived fibrin sealant and is sold as a frozen liquid, requiring less than one minute's preparation time after thawing. The product will be marketed in Europe by Johnson & Johnson subsidiary Ethicon, as it is in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze